How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Female Sexual Dysfunction Treatment Market
- By Treatment Type: Pharmacological Treatments, Hormone Replacement Therapy, Psychological Counseling, Medical Devices, Complementary and Alternative Medicine
- By Drug Class: Phosphodiesterase Type 5 Inhibitors, Flibanserin, Bremelanotide, Estrogen Therapy, Testosterone Therapy
- By Route of Administration: Oral, Topical, Intranasal, Injectable
- By Indication: Hypoactive Sexual Desire Disorder (HSDD), Female Sexual Arousal Disorder (FSAD), Female Orgasmic Disorder (FOD), Sexual Pain Disorders
- By End User: Hospitals, Specialty Clinics, Gynecology Clinics, Home Care Settings
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmacological Treatments leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Female Sexual Dysfunction Treatment Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Drug Class 5
Route of Administration 4
Indication 4
End User 4
Companies profiled
Hims & Hers Health Inc.
Sprout Pharmaceuticals (a Pfizer company)
AMAG Pharmaceuticals Inc.
Bayer AG
Endo International plc
Revive Therapeutics Ltd.
Palatin Technologies Inc.
Mylan N.V. (now part of Viatris)
AbbVie Inc.
Lilly (Eli Lilly and Company)
TherapeuticsMD Inc.
Mediherb (a division of Integria Healthcare)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Hims & Hers Health Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Sprout Pharmaceuticals (a Pfizer company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AMAG Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Endo International plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Revive Therapeutics Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Palatin Technologies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Lilly (Eli Lilly and Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →TherapeuticsMD Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Mediherb (a division of Integria Healthcare)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Hologic Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Mundipharma International Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Ferring Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,760M by 2033 · 7.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmacological Treatments57.9
- Hormone Replacement Therapy9.5
- Psychological Counseling15.0
- Medical Devices9.4
- Complementary and Alternative Medicine8.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,091M → $1,852M · 6.8%
Europe$760.7M → $1,191M · 5.8%
Asia Pacific$694.6M → $1,312M · 8.3%
Latin America$430.0M → $826.9M · 8.5%
Middle East and Africa$330.7M → $647.6M · 8.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.142026
7.152027
7.172028
7.162029
7.182030
7.192031
7.212032
7.222033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Hims & Hers Health Inc.13.6
- Sprout Pharmaceuticals (a Pfizer company)21.2
- AMAG Pharmaceuticals Inc.10.1
- Bayer AG11.1
- Endo International plc11.4
- Revive Therapeutics Ltd.4.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type26.0%
Drug Class16.7%
Route of Administration15.1%
Indication16.9%
End User25.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.8
- Europe20.4
- Asia Pacific22.5
- Latin America14.2
- Middle East and Africa11.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Hims & Hers Health Inc. | 98 | 94 | 74 | 96 | 75 | 94 | 89 |
| Sprout Pharmaceuticals (a Pfizer company) | 76 | 81 | 71 | 79 | 76 | 69 | 75 |
| AMAG Pharmaceuticals Inc. | 67 | 88 | 84 | 67 | 83 | 70 | 77 |
| Bayer AG | 58 | 78 | 60 | 70 | 67 | 81 | 69 |
| Endo International plc | 66 | 69 | 72 | 59 | 63 | 60 | 65 |
| Revive Therapeutics Ltd. | 69 | 66 | 60 | 65 | 55 | 52 | 61 |
| Palatin Technologies Inc. | 59 | 64 | 47 | 59 | 65 | 58 | 59 |
| Mylan N.V. (now part of Viatris) | 50 | 42 | 45 | 59 | 55 | 43 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Hims & Hers Health Inc.
- Sprout Pharmaceuticals (a Pfizer company)
- AMAG Pharmaceuticals Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Hims & Hers Health Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Sprout Pharmaceuticals (a Pfizer company) | ◐ | ◐ | − | ✓ | ◐ | ◐ |
| AMAG Pharmaceuticals Inc. | − | ✓ | ✓ | ◐ | ✓ | ✓ |
| Bayer AG | − | ◐ | ◐ | ◐ | ✓ | ◐ |
| Endo International plc | ◐ | ◐ | ◐ | − | − | − |
| Revive Therapeutics Ltd. | − | − | − | ◐ | − | ◐ |
| Palatin Technologies Inc. | − | − | ◐ | ◐ | − | − |
| Mylan N.V. (now part of Viatris) | ◐ | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Hims & Hers Health Inc.89
2AMAG Pharmaceuticals Inc.77
3Sprout Pharmaceuticals (a Pfizer company)75
4Bayer AG69
5Endo International plc65
6Revive Therapeutics Ltd.61
7Palatin Technologies Inc.59
8Mylan N.V. (now part of Viatris)49
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Hims & Hers Health Inc.
Challenger3
Strong scale, closing on the leaders.
Sprout Pharmaceuticals (a Pfizer company)AMAG Pharmaceuticals Inc.Bayer AG
Contender3
Focused players with pockets of strength.
Endo International plcRevive Therapeutics Ltd.Palatin Technologies Inc.
Niche1
Specialists in a single segment or region.
Mylan N.V. (now part of Viatris)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Female Sexual Dysfunction Treatment Market — a $486M beachhead inside a $8.48B market.
Beachhead (SOM)$486Mobtainable near-term
Serviceable (SAM)$2.96Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Pharmacological Treatments
Best fit — highest urgency & budget in Treatment Type.
Economic buyer79 fit
Hormone Replacement Therapy
Strong fit — clear ROI and a fast path to value.
End user64 fit
Psychological Counseling
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales41%
Partner / channel30%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Female Sexual Dysfunction Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified23%
Evaluation14%
Closed-won5%
$8.8KCAC
$32KLTV
3.6:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Female Sexual Dysfunction Treatment Market is a durable-growth opportunity — $3.19B by 2033, compounding at 9.9%.
TAM · 2025$1.50Btoday
TAM · 2033$3.19Bforecast
CAGR9.9%2027–2033
Cumulative$20.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.19BTotal addressable market
SAM$1.28BServiceable available market
SOM$232MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.9% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.19BLarge & growingTAM by 2033 at 9.9% CAGR
$1.28BServiceable nowreachable with today’s model
$232MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.49BBear6.4% CAGR
$3.19BBase9.9% CAGR
$4.08BBull13.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Female Sexual Dysfunction Treatment Market — a $4.52B market by 2033. Plan: grow share from 10.1% to 16.2%.
Market size · 2033$4.52Btotal addressable
Market CAGR8.3%2027–2033
Target share16.2%from 10.1% today
Revenue ambition$733Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.1% | 16.2% | Ahead |
| Revenue | $495M | $733M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.6% | 43.4% | Ahead |
| Customer retention | 91.9% | 93.8% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $79M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Female Sexual Dysfunction Treatment Market conversation — a $6.80B market you can size, segment and defend in minutes.
Market size · 2033$6.80Btotal opportunity
Growth4.8%CAGR to 2033
Addressable buyers1,285+accounts in scope
Typical ROI7.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.5×return on cost, year one
< 4 mopayback period
$60K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Hims & Hers Health Inc.Sprout Pharmaceuticals (a Pfizer company)AMAG Pharmaceuticals Inc.Bayer AGEndo International plcRevive Therapeutics Ltd.Palatin Technologies Inc.Mylan N.V. (now part of Viatris)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Female Sexual Dysfunction Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Female Sexual Dysfunction Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Age-Related Macular Degeneration (AMD) Therapeutics Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportUpper Respiratory Tract Infection Treatment Market
Market size, share, segmentation and regional forecast.
$933M market · 2025 base year
View reportVascular Endothelial Growth Factor (VEGF) Inhibitors Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportSelective Serotonin Reuptake Inhibitors (SSRIs) Market
Market size, share, segmentation and regional forecast.
$528M market · 2025 base year
View reportAtherosclerosis Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCanine Dilated Cardiomyopathy Drug Market
Market size, share, segmentation and regional forecast.
$322M market · 2025 base year
View reportDenture Fixative Cream Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportCollyrium Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportAI Solutions for Healthcare Market
Market size, share, segmentation and regional forecast.
$477M market · 2025 base year
View reportMontelukast Intermediate Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportAi Solutions for Cardiovascular Diseases Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportInsomnia Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.